CLAIM CARD
Within the corpus, a notable tension exists regarding the net clinical benefit, particularly in advanced renal disease. Furthermore, pharmacovigilance reporting identified bleeding disorders as a newly recognized adverse event, with elevated PT/INR values observed within 14 days to four months of therapy initiation, even without anticoagulant medication (Al-Omari 2026). The contrast between positive signals from pooled analyses of selected trials and null or safety-concern signals from real-world cohorts and adverse event reports underscores the complexity of applying these therapies across heterogeneous patient populations. These disagreements highlight the need for careful patient selection and monitoring in clinical practice.
Evidence grade: exploratory
Contradiction status: none
Publication: edeb045d-18ed-49dc-95b6-57f76783ce2b
Provenance: Derivation Web chain
Citation Support
source_1Solomon 2026source_2Din 2026source_3Li 2025source_4Mei 2025source_5Chung 2024